Company also announces first commercial
agreements for the Virtual Care Suite in the United States
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced the expansion of its Artificial
Intelligence (AI)-powered weight loss coach, Coach Iris, to support
patients prescribed GLP-1s and other anti-obesity medications and
the first commercial agreements for its Virtual Care Suite (VCS) in
the United States. With this update to Coach Iris, patients now
have access to 24/7 personalized coaching and guidance specific to
GLP-1s and other anti-obesity medications, such as treatment
duration, side effects, and consequences of stopping their
treatment. They can also engage with Coach Iris for tailored meal
plans, recipes, exercise routines, stress management techniques,
and motivational insights.
Coach Iris is part of the VCS, a dynamic weight-loss management
suite powered by AI and featuring remote patient monitoring,
predictive analytics, telehealth, and care team collaboration. The
VCS is available to healthcare professionals offering GLP-1 and
other anti-obesity medication therapy, bariatric surgery, and
weight loss devices.
“I have seen firsthand how difficult it is for providers to
offer best-in-class care for patients living with obesity. It
demands close follow-up and lifestyle modification coaching at
scale for sustained results,” said Dr. Shantanu Gaur, Founder and
CEO of Allurion. “We believe VCS and, specifically, Coach Iris, can
help ease this burden for them. We are excited to now work with our
U.S. clinical partners to help them achieve better, more
sustainable weight loss outcomes for their patients.”
Dr. Christopher McGowan, a triple board-certified physician in
internal medicine, gastroenterology, and obesity medicine based in
North Carolina and founder of True You Weight Loss, chose to
integrate VCS and Coach Iris into his treatment algorithm. “As part
of a clinical team of weight loss experts that provides minimally
invasive and non-surgical weight loss options, we have a diverse
patient population that requires personalized care and attention,”
said Dr. McGowan. “Allurion’s Virtual Care Suite equips us with
digital capabilities to provide even deeper, personalized care for
our patients.”
According to a recent study by Blue Cross Blue Shield, 58% of
patients discontinue use of GLP-1s before reaching a clinically
meaningful health benefit, and 30% of patients discontinued use of
the medications within the first month. Those who saw their doctor
more often were more likely to continue the treatment, emphasizing
the need for greater care management.
Dr. Alexander Shapsis, a triple board-certified physician and
President of Atlantic Gastroenterology and EndoSlim Clinic based in
New York, chose VCS, in part, to support his GLP-1 patients.
“GLP-1s and other anti-obesity treatments demonstrate the most
effective results when they are integrated into a holistic weight
loss program,” said Dr. Shapsis. “This requires seamless
communication between the provider and patients. We chose
Allurion’s VCS and its remote patient monitoring technology because
the platform was built specifically for weight loss clinics and
properly supports the needs of my staff and patients.”
In an Allurion study, 87% of providers who used the VCS reported
increased patient accountability, 88% reported increased
efficiencies in their practice, and 82% reported increased patient
engagement. “We are committed to adopting innovative technologies
that enhance patient care. We immediately saw the immense value of
Coach Iris and how it will help our patients stay engaged
throughout their weight loss journey,” said Paul Barros, Co-Founder
and CEO of Pivot Weight Loss. “This multi-purposed, digital tool
works in tandem with our bariatric-trained dieticians, ensuring a
blend of expert guidance and AI technology.”
“Weight loss clinics in the United States are experiencing
explosive growth due to high patient demand for a number of
therapies, including GLP-1s,” said Brian Conyer, VP of Digital
Health at Allurion. “As a result, we believe there is a significant
opportunity for our digital products and AI-powered technology to
help clinics and providers meet the demand, maintain positive
patient outcomes, and continue to grow.”
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less intragastric
balloon for weight loss, and offers access to the Allurion Virtual
Care Suite including the Allurion Mobile App for consumers,
Allurion Insights for health care providers featuring the Coach
Iris AI Platform, and the Allurion Connected Scale. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage weight
loss therapy for patients regardless of their treatment plan:
gastric balloon, surgical, medical or nutritional. The Allurion
Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
About True You Weight Loss
True You Weight Loss is the nation’s first and only
physician-founded medical practice exclusively focused on providing
non-surgical, state-of-the-art weight loss procedures and support.
Dr. Lauren Donnangelo, Dr. Daniel Maselli, and Dr. Christopher
McGowan are among the few physicians in the nation who are triple
board-certified in internal medicine, gastroenterology, and obesity
medicine, and leaders in the area of endobariatrics.
About Atlantic Gastroenterology
Atlantic Gastroenterology is a state-of-the-art clinic located
in the New York area. The practice specializes in all aspects of
gastroenterology, hepato-billiary diseases, and hepatology.
About Pivot Weight Loss
Pivot Weight Loss provides a modernized bariatric surgery
journey to help patients achieve weight loss goals by combining
expert surgeons, technology, and a friendly support team trained to
encourage and educate, not judge.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding the ability of the Allurion Program,
including the VCS, to improve patient and clinical outcomes,
including outcome improvements over time, the impact of a behavior
change coaching skills course, and the impact of gLP-1s on the
Allurion Program. Forward-looking statements are predictions,
projections and other statements about future events that reflect
the current beliefs and assumptions of Allurion’s management based
on information currently available to them and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future results or developments to differ materially from the
forward-looking statements in this communication, including but not
limited to (i) the ability of Allurion to obtain and maintain
regulatory approvals for and successfully commercialize the
Allurion Program, including the Allurion Balloon and the VCS, (ii)
the timing of, and results from, our clinical studies and trials,
(iii) the evolution of the markets in which Allurion competes, (iv)
the ability of Allurion to defend its intellectual property, (v)
the impact of the COVID-19 pandemic, the Russia and Ukraine war,
and the Israel-Hamas conflict on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities,
including those for the VCS platform, and (vii) the risk of
economic downturns and a changing regulatory landscape in the
highly competitive industry in which Allurion operates. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Allurion’s
Annual Report on Form 10-K filed on March 26, 2024 (as subsequently
amended) and other documents filed by Allurion from time to time
with the U.S. Securities and Exchange Commission. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Allurion assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Allurion does not give
any assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530248268/en/
Global Media: Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investors: Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
